Page last updated: 2024-11-04

3-phenyllactic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Phenyllactic acid (3-PLA) is a chiral compound found in various biological sources, including human urine, milk, and bacteria. It is a derivative of lactic acid with a phenyl group attached to the third carbon atom. 3-PLA is studied for its potential therapeutic applications. It is known to exhibit antioxidant and anti-inflammatory properties. 3-PLA has been investigated for its role in preventing neurodegenerative diseases, such as Alzheimer's disease, and for its potential in treating inflammatory bowel disease. The synthesis of 3-PLA is typically achieved through chemical methods, such as the reduction of phenylpyruvic acid or the enzymatic conversion of phenylalanine. Studies have also explored the biosynthesis of 3-PLA in bacteria, with potential applications in the production of this compound through fermentation.'
```

3-phenyllactic acid: alpha-hydroxy analog of phenylalanine; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-phenyllactic acid : A 2-hydroxy monocarboxylic acid that is lactic acid in which one of the methyl hydrogens is substituted by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3848
CHEMBL ID1778420
CHEBI ID25998
SCHEMBL ID57558
MeSH IDM0068589

Synonyms (87)

Synonym
dl-beta-phenyllactic acid
CHEBI:25998 ,
2-hydroxy-3-phenylpropanoic acid
3-phenyllactic acid
2-hydroxy-3-phenylpropionic acid
beta-phenyllactic acid
ba 2653
dl-phenyllactic acid
dl-.alpha.-hydroxycinnamic acid
nsc-2627
dl-.beta.-phenyllactic acid
828-01-3
nsc2627
dl-3-phenyllactic acid
dl-3-phenyllactic acid, >=98%
8C1DB5C8-C19C-4963-8F3E-B683EAB4B04F
lactic acid, 3-phenyl-
b-phenyllactic acid
CHEMBL1778420
A840451
benzenepropanoic acid, a-hydroxy-
156-05-8
2-hydroxy-3-phenyl-propionic acid
AKOS009103896
(1)-3-phenyllactic acid
lactic acid, 3-phenyl-, dl-
unii-sc6t4o59bk
nsc 2627
einecs 212-580-4
benzenepropanoic acid, alpha-hydroxy-
ai3-50440
dl-alpha-hydroxycinnamic acid
sc6t4o59bk ,
FT-0624395
FT-0625405
FT-0627624
AM20060840
SCHEMBL57558
(2rs)-2-hydroxy-3-phenylpropanoic acid
3-phenyl-2-hydroxypropionic acid
benzyl-glycolic acid
(+/-)-2-hydroxy-3-phenylpropanoic acid
(rs)-2-hydroxy-3-phenyl propanoic acid
2-hydroxy-3-phenyl-propanoic acid
beta-phenyl lactic acid
(s)-2-hydroxy-3-phenyl-propionic acid
W-203882
(+-)-3-phenyllactic acid
(+/-)-2-hydroxy-3-phenylpropionic acid
2-hydroxy-3-phenylpropanoic acid #
benzenepropanoic acid, .alpha.-hydroxy-, (s)-
mfcd00004244
F9995-2643
mfcd00065928
(+/-)-3-phenyllactic acid
benzenepropanoic acid, .alpha.-hydroxy-
(rs)-2-hydroxy-3-phenyl-propionic acid
dl-2-hydroxy-3-phenylpropionate
a-hydroxybenzenepropanoic acid
3-phenyl-2-hydroxypropanoate
dl-b-phenyllactate
b-phenyllactate
alpha-hydroxybenzenepropanoate
dl-2-hydroxy-3-phenylpropionic acid
beta-phenyllactate
dl-3-phenyllactate
alpha-hydroxybenzenepropanoic acid
a-hydroxybenzenepropanoate
3-phenyl-2-hydroxypropanoic acid
dl-b-phenyllactic acid
2-hydroxy-3-phenylpropionate
dl-beta-phenyllactate
CS-W017878
HY-W017162
dl--phenyllactic acid
SY020879
SY036063
SY021341
DTXSID30862436
3-phenyl-dl-lactic acid
AS-19567
Q10395585
AC1610
d-beta-phenyllactic acid
(r)-2-hydroxy-3-phenyl-propionic acid
EN300-124810
Z788000648

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Moreover, a moderate reduction of the bioavailability of aflatoxin AFB1 was detected."( Functional characterization of Lactobacillus plantarum ITEM 17215: A potential biocontrol agent of fungi with plant growth promoting traits, able to enhance the nutritional value of cereal products.
Bernardi, C; Brasca, M; De Noni, I; Fortina, MG; Masotti, F; Passera, A; Quattrini, M; Ricci, G; Stuknytė, M; Vallone, L, 2018
)
0.48
" We demonstrate that D-PLA from such alimentary sources is well absorbed from the human gut leading to high plasma and urine levels and triggers pertussis toxin-sensitive migration of primary human monocytes in an HCA3-dependent manner."( Metabolites of lactic acid bacteria present in fermented foods are highly potent agonists of human hydroxycarboxylic acid receptor 3.
Çakir, MV; Ceglarek, U; Gaudl, A; Heintz-Buschart, A; Jäger, E; Krumbholz, P; Peters, A; Rothemund, S; Schöneberg, T; Stäubert, C, 2019
)
0.51
" The aim of the present study was to evaluate the bioaccessibility and bioavailability of bioactive compounds from yellow mustard flour and milk whey both with and without LAB fermentation."( Bioaccessibility and bioavailability of bioactive compounds from yellow mustard flour and milk whey fermented with lactic acid bacteria.
Escrivá, L; Font, G; Lozano, M; Manyes, L; Meca, G; Vila-Donat, P, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-hydroxy monocarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID597946Cytotoxicity against human Jurkat T cells after 36 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Monoterpenoids from the aerial parts of Aruncus dioicus var. kamtschaticus and their antioxidant and cytotoxic activities.
AID1130306Inhibition of glycolic acid oxidase (unknown origin) assessed as enzyme-mediated reduction of NaDCIP by sodium glycolate after 1 to 3 mins by spectrophotometer analysis1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Quantitative structure-activity relationships involving the inhibition of glycolic acid oxidase by derivatives of glycolic and glyoxylic acids.
AID1501904Antioxidant activity assessed as inhibition of ferrous chloride-induced lipid peroxidation in DHA-PA labelled SLPC large unilamellar vesicle measured over 21 mins by fluorescence assay2017Journal of natural products, 09-22, Volume: 80, Issue:9
Lipid Peroxidation and Cyclooxygenase Enzyme Inhibitory Compounds from Prangos haussknechtii.
AID1495021Inhibition of Aeromonas hydrophila CphA at 100 uM using fluorogenic cephalosporin as substrate2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
AID1495020Inhibition of recombinant bacterial NDM1 expressed in Escherichia coli BL21 (DE3) cells at 100 uM using FC5 as fluorogenic reporter substrate preincubated at 10 to 300 mins followed by substrate addition2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
AID1495018Inhibition of recombinant bacterial BC2 expressed in Escherichia coli BL21 (DE3) cells at 100 uM using FC4-FC5 as substrate by fluorescence-based assay2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
AID1495017Inhibition of recombinant bacterial IMP1 expressed in Escherichia coli BL21 (DE3) cells at 100 uM using FC4-FC5 as substrate by fluorescence-based assay2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
AID1597857Inhibition of Staphylococcus aureus pyruvate carboxylase expressed in Escherichia coli BL21(DE3) assessed as FVB-OAA adduct formation using pyruvate as substrate by Fast violet B assay2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Evaluation of α-hydroxycinnamic acids as pyruvate carboxylase inhibitors.
AID750756Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC.
AID597947Antioxidant activity assessed as DPPH radical scavenging activity after 10 mins2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
Monoterpenoids from the aerial parts of Aruncus dioicus var. kamtschaticus and their antioxidant and cytotoxic activities.
AID750752Dissociation constant, pKa of the compound2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC.
AID1495016Inhibition of recombinant full-length bacterial His6-tagged SPM1 (29 to 276 residues) expressed in Escherichia coli BL21 (DE3) cells at 100 uM using FC4-FC5 as substrate by fluorescence-based assay2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
AID750755Inhibition of Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus laevis oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents at 1 mM after 30 secs by voltage clamp technique2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC.
AID1495019Inhibition of recombinant full-length bacterial His6-tagged VIM2 (27 to 266 residues) expressed in Escherichia coli BL21 (DE3) cells at 100 uM using FC4-FC5 as substrate by fluorescence-based assay2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-β-lactamases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (131)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (12.98)18.7374
1990's9 (6.87)18.2507
2000's21 (16.03)29.6817
2010's53 (40.46)24.3611
2020's31 (23.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.22 (24.57)
Research Supply Index4.92 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index63.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.49%)5.53%
Reviews3 (2.24%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other129 (96.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]